A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Phase 1

• Conditions: Anticoagulant
• Interventions: Drug: Lixiana(D006); Drug: CKD-344

• Registration Number: NCT04673695
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344

Detailed Description

A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of CKD-344.

Study Timeline

• Study First Submitted: 2020-11-08
• Study Start: 2020-11-13
• Status Verified: 2020-12
• Study First Submitted QC: 2020-12-16
• Last Update Submitted: 2020-12-16
• Study First Posted: 2020-12-17
• Last Update Posted: 2020-12-17
• Primary Completion: 2020-12-26
• Study Completion: 2021-01-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Healthy adult volunteers aged ≥ 19 years
2. Weight ≥60kg, with calculated body mass index(BMI) of 18 to 30 kg/m2
3. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.
4. Those who are eligible for clinical trials based on laboratory (hematology, blood coagulation, blood chemistry, serology, urinalysis) at screening.
5. Those who agree to contraception during the participation of clinical trial.
6. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.

Exclusion Criteria

1. Those who has a medical evidence or a history of clinically significant gastrointestinal, cardiovascular, endocrine, pulmonary, hematological, infective disease, renal, urinary, psychiatric, neurologic, skeleto-muscular, immune, etc.
2. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.
3. Those who had taken prescription or nonprescription drugs within 10 days prior to the first dose of investigational product.
4. Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.
5. Those who donated whole blood within 2 months or blood components within 1 month prior to the first dose of the investigational product.
6. Those who exceed an alcohol and cigarette consumption than below criteria. A. Alcohol: Man- 21 glasses/week, Woman - 14 glasses/week B. Smoking: 20 cigarettes/day
7. Those who exceeds 2 times the upper limit of the reference range of AST(or ALT) or 1.5 times the upper limit of the reference range of γ-GTP.
8. Those who have hypersensitivity to the drug or the drug ingredient, such as anaphylactic reactions.
9. Those who have specific disease(e.g. severe bleeding disorder, severe renal/hepatic disease, uncontrolled severe hypertension, etc.)
10. Those who were deemed inappropriate to participate in the study by the investigator.
11. Those who have a pregnant or nursing woman.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Group A	Lixiana(D006)	1. Period 1: Reference drug(Lixiana 60 mg) 2. Period 2: Test drug(CKD-344 60 mg)
Group B	Lixiana(D006)	1. Period 1: Test drug(CKD-344 60 mg) 2. Period 2: Reference drug(Lixiana 60 mg)
Group A	CKD-344	1. Period 1: Reference drug(Lixiana 60 mg) 2. Period 2: Test drug(CKD-344 60 mg)
Group B	CKD-344	1. Period 1: Test drug(CKD-344 60 mg) 2. Period 2: Reference drug(Lixiana 60 mg)

Primary Outcome Measures

Name	Time	Method
Cmax	predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose	The maximum concentration observed of CKD-344 over blood sampling time.
AUCt(Area Under Curve last) of CKD-344	predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose	Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.

Trial Locations

Locations (1)

Yook-Hwan Noh; 🇰🇷 Seoul, Korea, Republic of